No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

(2015)   HEPATOLOGY

O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks

(2015) E. Lawitz et al.   JOURNAL OF HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2015

(2015)   JOURNAL OF HEPATOLOGY

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapy for Hepatitis C — The Costs of Success

(2014) Jay H. Hoofnagle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

(2014) T. R. O'Brien et al.   Open Forum Infectious Diseases